The SCYLLA cellular bone matrices are viable allogeneic bone allografts containing viable bone-derived cells. Each SCYLLA product contains the three key components that are ideal for bone formation:

  1. An osteoconductive three-dimensional scaffold with cortical and cancellous components

  2. A demineralized bone scaffold with osteoinductive potential, which provides exposure of signaling molecules and bone morphogenetic proteins1

  3. Bone-derived cells to support osteogenic healing processes

Key Features of SCYLLA Product Line

  • Three (3) unique scaffold blends for optimal handling characteristics: SCYLLA, SCYLLA Moldable, SCYLLA-F Moldable.
  • Proprietary, optimized bone microparticulate size range of 100-300 μm.2
  • Novel DMSO-free cryoprotectant, with no rinsing and decanting steps required prior to use.
  • Average cell viability of the cell component exceeds 80% post-thaw.3
  • Minimum of 150,000 viable cells per cc of allograft post-thaw.3
  • Convenient handling and preparation in the OR, with total preparation time on the back table of less than 20 minutes.
  • Four (4) hour working window for implantation after thaw without loss of cell viability.3
  • Product shelf-life is two (2) years from date of processing when stored at -65°C or colder.
Screen Shot 2019-05-29 at 4.18.17 PM.png


  1. Gruskin, E., et al., Demineralized Bone Matrix in Bone Repair, History and Use. Advanced Drug Delivery Reviews, 2012. 64: 1063-1077.

  2. Malinin, T.I., et al., Particulate Bone Allograft Incorporation In Regeneration of Osseous Defects; Importance of Particle Sizes. The Open Orthopaedics Journal, 2007. 1: p. 19-24.

  3. Data on file at Vivex Biomedical, Inc.